The Experts below are selected from a list of 5709 Experts worldwide ranked by ideXlab platform
Xingzhong Zhao - One of the best experts on this subject based on the ideXlab platform.
-
enhanced isolation and release of fetal nucleated red blood cells using multifunctional nanoparticle based microfluidic device for non invasive Prenatal Diagnostics
Sensors and Actuators B-chemical, 2019Co-Authors: Keke Chen, Lin Cheng, Zixiang Wang, Yuanzhen Zhang, Xingzhong ZhaoAbstract:Abstract Fetal nucleated red blood cells (fNRBC) in maternal peripheral blood has the potential for non-invasive Prenatal Diagnostics (NIPD), given its intrinsic nature carrying total genetic information of the fetus. Unfortunately, the scarcity of fNRBCs in maternal blood circulation greatly hinders the effective isolation of fNRBCs and its further uses for clinical Prenatal Diagnostics. Herein, we developed a gelatin nanoparticles (GNPs) decorated microchip that modified with anti-CD147 as specific capture antibody to efficiently isolate fNRBCs from maternal peripheral blood. The corrugated GNP nanocoating on the walls of the channel, together with herringbone grooves in the continuous curved channel design, produced enhanced interactions between fNRBC and the device for better cell capture performance. Furthermore, the captured cells could be gently released for subsequent off-chip analyses, using an enzymatic treatment to dissolve the biodegradable GNP nanocoating. Significant target cell capture efficiency (>80%), release efficiency (∼89%) and purity (∼85%) as well as a high viability of >90% were achieved using simulated spiked samples. fNRBCs were detected from a series of maternal peripheral blood samples ranging from 7 to 13 weeks of gestation, and the diagnostic application for fetal chromosomal disorders was demonstrated. Our strategy may provide new insights into developing an approach to recover fNRBCs from early pregnancy for improved cell-based NIPD.
-
highly sensitive and rapid isolation of fetal nucleated red blood cells with microbead based selective sedimentation for non invasive Prenatal Diagnostics
Nanotechnology, 2018Co-Authors: Zheng Ao, Lin Cheng, Zixiang Wang, Yuanzhen Zhang, Zhaobo He, Qinqin Huang, Qianfang Meng, Xingzhong ZhaoAbstract:: Non-invasive Prenatal Diagnostics (NIPD) has been an emerging field for Prenatal diagnosis research. Carrying the whole genome coding of the fetus, fetal nucleated red blood cells (FNRBCs) have been pursued as a surrogate biomarker traveling around in maternal blood. Here, by combining a unique microbead-based centrifugal separation and enzymatic release, we demonstrated a novel method for FNRBC isolation from the blood samples. First, the gelatin-coated silica microbeads were modified with FNRBC-specific antibody (anti-CD147) to capture the target cells in the blood samples. Then, the density difference between microbead-bound FNRBCs and normal blood cells enables the purification of FNRBCs via an improved high-density percoll-based separation. The non-invasive release of FNRBCs can then be achieved by enzymatically degrading the gelatin film on the surface of the microbeads, allowing a gentle release of the captured target cells with as high as 84% efficiency and ∼80% purity. We further applied it to isolate fetal cells from maternal peripheral blood. The released cells were analyzed by real-time polymerase chain reaction to verify their fetal origin and fluorescent in situ hybridization to detect fetal chromosome disorders. This straightforward and reliable alternative platform for FNRBC detection may have the potential for realizing facile NIPD.
-
fetal nucleated red blood cell analysis for non invasive Prenatal Diagnostics using a nanostructure microchip
Journal of Materials Chemistry B, 2017Co-Authors: Zhaobo He, Yuanzhen Zhang, Chun Feng, James P Lata, Rongxiang He, Qinqin Huang, Xiaolei Yu, Tony Jun Huang, Xingzhong ZhaoAbstract:Cell-free DNA has been widely used in non-invasive Prenatal Diagnostics (NIPD) nowadays. Compared to these incomplete and multi-source DNA fragments, fetal nucleated red blood cells (fNRBCs), once as an aided biomarker to monitor potential fetal pathological conditions, have re-attracted research interest in NIPD because of their definite fetal source and the total genetic information contained in the nuclei. Isolating these fetal cells from maternal peripheral blood and subsequent cell-based bio-analysis make maximal genetic diagnosis possible, while causing minimal harm to the fetus or its mother. In this paper, an affinity microchip is reported which uses hydroxyapatite/chitosan nanoparticles as well as immuno-agent anti-CD147 to effectively isolate fNRBCs from maternal peripheral blood, and on-chip biomedical analysis was demonstrated as a proof of concept for NIPD based on fNRBCs. Tens of fNRBCs can be isolated from 1 mL of peripheral blood (almost 25 mL−1 in average) from normal pregnant women (from the 10th to 30th gestational week). The diagnostic application of fNRBCs for fetal chromosome disorders (Trisomy 13 and 21) was also demonstrated. Our method offers effective isolation and accurate analysis of fNRBCs to implement comprehensive NIPD and to enhance insights into fetal cell development.
Yuanzhen Zhang - One of the best experts on this subject based on the ideXlab platform.
-
enhanced isolation and release of fetal nucleated red blood cells using multifunctional nanoparticle based microfluidic device for non invasive Prenatal Diagnostics
Sensors and Actuators B-chemical, 2019Co-Authors: Keke Chen, Lin Cheng, Zixiang Wang, Yuanzhen Zhang, Xingzhong ZhaoAbstract:Abstract Fetal nucleated red blood cells (fNRBC) in maternal peripheral blood has the potential for non-invasive Prenatal Diagnostics (NIPD), given its intrinsic nature carrying total genetic information of the fetus. Unfortunately, the scarcity of fNRBCs in maternal blood circulation greatly hinders the effective isolation of fNRBCs and its further uses for clinical Prenatal Diagnostics. Herein, we developed a gelatin nanoparticles (GNPs) decorated microchip that modified with anti-CD147 as specific capture antibody to efficiently isolate fNRBCs from maternal peripheral blood. The corrugated GNP nanocoating on the walls of the channel, together with herringbone grooves in the continuous curved channel design, produced enhanced interactions between fNRBC and the device for better cell capture performance. Furthermore, the captured cells could be gently released for subsequent off-chip analyses, using an enzymatic treatment to dissolve the biodegradable GNP nanocoating. Significant target cell capture efficiency (>80%), release efficiency (∼89%) and purity (∼85%) as well as a high viability of >90% were achieved using simulated spiked samples. fNRBCs were detected from a series of maternal peripheral blood samples ranging from 7 to 13 weeks of gestation, and the diagnostic application for fetal chromosomal disorders was demonstrated. Our strategy may provide new insights into developing an approach to recover fNRBCs from early pregnancy for improved cell-based NIPD.
-
highly sensitive and rapid isolation of fetal nucleated red blood cells with microbead based selective sedimentation for non invasive Prenatal Diagnostics
Nanotechnology, 2018Co-Authors: Zheng Ao, Lin Cheng, Zixiang Wang, Yuanzhen Zhang, Zhaobo He, Qinqin Huang, Qianfang Meng, Xingzhong ZhaoAbstract:: Non-invasive Prenatal Diagnostics (NIPD) has been an emerging field for Prenatal diagnosis research. Carrying the whole genome coding of the fetus, fetal nucleated red blood cells (FNRBCs) have been pursued as a surrogate biomarker traveling around in maternal blood. Here, by combining a unique microbead-based centrifugal separation and enzymatic release, we demonstrated a novel method for FNRBC isolation from the blood samples. First, the gelatin-coated silica microbeads were modified with FNRBC-specific antibody (anti-CD147) to capture the target cells in the blood samples. Then, the density difference between microbead-bound FNRBCs and normal blood cells enables the purification of FNRBCs via an improved high-density percoll-based separation. The non-invasive release of FNRBCs can then be achieved by enzymatically degrading the gelatin film on the surface of the microbeads, allowing a gentle release of the captured target cells with as high as 84% efficiency and ∼80% purity. We further applied it to isolate fetal cells from maternal peripheral blood. The released cells were analyzed by real-time polymerase chain reaction to verify their fetal origin and fluorescent in situ hybridization to detect fetal chromosome disorders. This straightforward and reliable alternative platform for FNRBC detection may have the potential for realizing facile NIPD.
-
fetal nucleated red blood cell analysis for non invasive Prenatal Diagnostics using a nanostructure microchip
Journal of Materials Chemistry B, 2017Co-Authors: Zhaobo He, Yuanzhen Zhang, Chun Feng, James P Lata, Rongxiang He, Qinqin Huang, Xiaolei Yu, Tony Jun Huang, Xingzhong ZhaoAbstract:Cell-free DNA has been widely used in non-invasive Prenatal Diagnostics (NIPD) nowadays. Compared to these incomplete and multi-source DNA fragments, fetal nucleated red blood cells (fNRBCs), once as an aided biomarker to monitor potential fetal pathological conditions, have re-attracted research interest in NIPD because of their definite fetal source and the total genetic information contained in the nuclei. Isolating these fetal cells from maternal peripheral blood and subsequent cell-based bio-analysis make maximal genetic diagnosis possible, while causing minimal harm to the fetus or its mother. In this paper, an affinity microchip is reported which uses hydroxyapatite/chitosan nanoparticles as well as immuno-agent anti-CD147 to effectively isolate fNRBCs from maternal peripheral blood, and on-chip biomedical analysis was demonstrated as a proof of concept for NIPD based on fNRBCs. Tens of fNRBCs can be isolated from 1 mL of peripheral blood (almost 25 mL−1 in average) from normal pregnant women (from the 10th to 30th gestational week). The diagnostic application of fNRBCs for fetal chromosome disorders (Trisomy 13 and 21) was also demonstrated. Our method offers effective isolation and accurate analysis of fNRBCs to implement comprehensive NIPD and to enhance insights into fetal cell development.
B P Robra - One of the best experts on this subject based on the ideXlab platform.
-
a preference based measure for test performance with an application to Prenatal Diagnostics
Statistics in Medicine, 2006Co-Authors: Stefan Felder, B P RobraAbstract:Clinical epidemiology generally uses the receiver operating characteristic curve to summarize the accuracy of a diagnostic test and to compare the relative performance of different tests. This paper extends this concept to include the utility gains and losses of true and false test outcomes over the range of a priori risk. A utility index is developed first in situations where test accuracy is exogenously given, second where the test cutpoint can be chosen by the clinician according to the patient's a priori risk and preferences. By integrating over the a priori risk range, we derive an overall measure for a test's performance weighted by utility gains and losses. An example in Prenatal Diagnostics finally illustrates the clinical uses of the novel approach. Integrating patients' preference into clinical decision making will lead to different cutpoints and different assessments of test performance compared to unweighted policies. Copyright © 2005 John Wiley & Sons, Ltd.
-
a priori risk and optimal test accuracy in Prenatal Diagnostics
Medical Decision Making, 2003Co-Authors: Stefan Felder, Andreas Werblow, B P RobraAbstract:The prevalence of fetal chromosome anomalies rises exponentially with the age of the pregnant woman. The risk of fetal anomalies can be specified using biochemical screening tests such as the triple test. This test substantially reduces the number of amniocenteses and proportionally the number of procedure-related miscarriages. However, disadvantages of the triple test include the utility loss of pregnant women who, following a false-negative test result, do not undergo amniocentesis and bear a disabled child as well as the intangible cost of a false-positive triple test. This paper employs a decision-analytic model to reveal the evaluation of this tradeoff, which is implicitly fixed by policy recommendations for a direct amniocentesis at maternal age of 35. It then determines the optimal level of cutoff risk for the triple test, and derives comparative static results: the optimal test accuracy decreases with increasing a-priori risk and increases with a rise in the miscarriage risk and in the woman's pre...
Zhaobo He - One of the best experts on this subject based on the ideXlab platform.
-
highly sensitive and rapid isolation of fetal nucleated red blood cells with microbead based selective sedimentation for non invasive Prenatal Diagnostics
Nanotechnology, 2018Co-Authors: Zheng Ao, Lin Cheng, Zixiang Wang, Yuanzhen Zhang, Zhaobo He, Qinqin Huang, Qianfang Meng, Xingzhong ZhaoAbstract:: Non-invasive Prenatal Diagnostics (NIPD) has been an emerging field for Prenatal diagnosis research. Carrying the whole genome coding of the fetus, fetal nucleated red blood cells (FNRBCs) have been pursued as a surrogate biomarker traveling around in maternal blood. Here, by combining a unique microbead-based centrifugal separation and enzymatic release, we demonstrated a novel method for FNRBC isolation from the blood samples. First, the gelatin-coated silica microbeads were modified with FNRBC-specific antibody (anti-CD147) to capture the target cells in the blood samples. Then, the density difference between microbead-bound FNRBCs and normal blood cells enables the purification of FNRBCs via an improved high-density percoll-based separation. The non-invasive release of FNRBCs can then be achieved by enzymatically degrading the gelatin film on the surface of the microbeads, allowing a gentle release of the captured target cells with as high as 84% efficiency and ∼80% purity. We further applied it to isolate fetal cells from maternal peripheral blood. The released cells were analyzed by real-time polymerase chain reaction to verify their fetal origin and fluorescent in situ hybridization to detect fetal chromosome disorders. This straightforward and reliable alternative platform for FNRBC detection may have the potential for realizing facile NIPD.
-
fetal nucleated red blood cell analysis for non invasive Prenatal Diagnostics using a nanostructure microchip
Journal of Materials Chemistry B, 2017Co-Authors: Zhaobo He, Yuanzhen Zhang, Chun Feng, James P Lata, Rongxiang He, Qinqin Huang, Xiaolei Yu, Tony Jun Huang, Xingzhong ZhaoAbstract:Cell-free DNA has been widely used in non-invasive Prenatal Diagnostics (NIPD) nowadays. Compared to these incomplete and multi-source DNA fragments, fetal nucleated red blood cells (fNRBCs), once as an aided biomarker to monitor potential fetal pathological conditions, have re-attracted research interest in NIPD because of their definite fetal source and the total genetic information contained in the nuclei. Isolating these fetal cells from maternal peripheral blood and subsequent cell-based bio-analysis make maximal genetic diagnosis possible, while causing minimal harm to the fetus or its mother. In this paper, an affinity microchip is reported which uses hydroxyapatite/chitosan nanoparticles as well as immuno-agent anti-CD147 to effectively isolate fNRBCs from maternal peripheral blood, and on-chip biomedical analysis was demonstrated as a proof of concept for NIPD based on fNRBCs. Tens of fNRBCs can be isolated from 1 mL of peripheral blood (almost 25 mL−1 in average) from normal pregnant women (from the 10th to 30th gestational week). The diagnostic application of fNRBCs for fetal chromosome disorders (Trisomy 13 and 21) was also demonstrated. Our method offers effective isolation and accurate analysis of fNRBCs to implement comprehensive NIPD and to enhance insights into fetal cell development.
Rob Willemsen - One of the best experts on this subject based on the ideXlab platform.
-
rapid fmr1 protein analysis of fetal blood an enhancement of Prenatal Diagnostics
Human Genetics, 1999Co-Authors: N Lambiris, Hartmut Peters, R Bollmann, G Leschik, J Leisti, Riitta Salonen, G Cobet, Ben A Oostra, Rob WillemsenAbstract:Fragile-X syndrome, a frequent cause of inherited mental retardation, is characterised in almost all cases by a CGG-repeat expansion that is located within the FMR-1 gene and that prevents the expression of fragile-X mental retardation protein (FMRP). We describe a test that simultaneously allows the rapid detection of FMRP in fetal lymphocytes and distinguishes these from fetal erythrocytes. Routine molecular genetic methods fail in the rare cases where protein expression is blocked, although there is no repeat expansion. Furthermore, they are unsuitable in cases of advanced pregnancy. Our test proves extremely valuable under both these circumstances.